Literature DB >> 12946951

Treatment of lysosomal storage disorders.

Atul B Mehta, Susan Lewis, Christine Laverey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12946951      PMCID： PMC188370          DOI： 10.1136/bmj.327.7413.462

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Enzyme-replacement therapy for Anderson-Fabry disease.

Authors:  G M Pastores; R Thadhani
Journal:  Lancet       Date:  2001-08-25       Impact factor: 79.321

Review 2.  New developments in the management of Anderson-Fabry disease.

Authors:  A Mehta
Journal:  QJM       Date:  2002-10

3.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

4.  Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

Authors:  T Cox; R Lachmann; C Hollak; J Aerts; S van Weely; M Hrebícek; F Platt; T Butters; R Dwek; C Moyses; I Gow; D Elstein; A Zimran
Journal:  Lancet       Date:  2000-04-29       Impact factor: 79.321

5.  Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.

Authors:  B Sachdev; T Takenaka; H Teraguchi; C Tei; P Lee; W J McKenna; P M Elliott
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

Review 6.  Anderson-Fabry disease.

Authors:  S H Morgan; M A Crawfurd
Journal:  BMJ       Date:  1988-10-08

7.  Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

Authors:  R Schiffmann; J B Kopp; H A Austin; S Sabnis; D F Moore; T Weibel; J E Balow; R O Brady
Journal:  JAMA       Date:  2001-06-06       Impact factor: 56.272
  7 in total
  3 in total

Review 1.  An overview on bone manifestations in Gaucher disease.

Authors:  Peter Mikosch; Derralynn Hughes
Journal:  Wien Med Wochenschr       Date:  2010-12

2.  Enzyme replacement therapy in India: Lessons and insights.

Authors:  M Muranjan; S Karande
Journal:  J Postgrad Med       Date:  2018 Oct-Dec       Impact factor: 1.476

3.  RECURRENT ATYPICAL OPTIC NEURITIS AS THE LEADING SIGN OF FABRY DISEASE.

Authors:  Iris Zavoreo; Miljenka Jelena Jurašić; Marijana Lisak; Ana Jadrijević Tomas; Ognjen Zrinščak; Vanja Bašić Kes
Journal:  Acta Clin Croat       Date:  2019-09       Impact factor: 0.780
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.